A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis

CLAO Journal

Volumn 23, Issue 1, 1997, Pages 31-36

  Asbell, Penny ^a   Howes, John ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Pharmos Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOTEPREDNOL ETABONATE; PLACEBO;

ALLERGIC REACTION; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTACT LENS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE ABNORMALITY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MUCUS SECRETION; PAPILLARY CONJUNCTIVITIS; PRACTICE GUIDELINE; PRURITUS; RANDOMIZED CONTROLLED TRIAL; TOPICAL DRUG ADMINISTRATION;

EID: 0031021022     PISSN: 07338902     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Allansmith MR, Korb DR, Greiner JV, et al: Giant papillary conjunctivitis in contact lens wearers. Am J Ophthalmol 1977;83:697-708.
2. Allansmith MR, Ross RN: Ocular allergy and mast cell stabilizers. Survey Ophthalmol 1986;30:229-244.
3. Donshik PC, Ballow M, Luistro A, et al: Treatment of contact lens-induced giant papillary conjunctivitis. CLAO J 1984;10:346-350.
4. Wood TS, Stewart RH, Bowman RW, et al: Suprofen treatment of contact lens-associated giant papillary conjunctivitis. Ophthalmology 1988;95:822-826.
5. Bodor N: Soft drugs: principles and methods for the design of safe drugs. Med Res Rev 1984;4:449-469.
6. Bodor N: Novel approaches to the design of safer drugs: Soft drugs and site-specific chemical delivery systems, in Anonymous New York, Academic Press, 1984, pp 255-329.
7. Druzgala P, Wu WM, Bodor N: Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes. Curr Eye Res 1991;10:933-937.
8. Bartlett JD, Horwitz B, Laibovitz R, et al: Intraocular pressure response to loteprednol etabonate in known steroid responders. J Ocul Pharmacol 1993;9:157-165.
9. Bartlett JD, Howes JF, Ghormley NR, et al: Safety and efficacy of loteprednol etabonate for treatment of papillae in contact lens-associated giant papillary conjunctivitis. Curr Eye Res 1993;12:312-321.
10. Newcombe RG, Duff GR: Eyes or patients? Traps for the unwary in the statistical analysis of ophthalmological studies. Br J Ophthalmol 1987;71:645-646.
11. Ederer F: Refereeing clinical research papers for statistical content. Am J Ophthalmol 1985;100:735-737.
12. Cochran WG: Some methods for strengthening the common Chi-square test. Biometrics 1954;10:417-451
13. Stewart RH, Smith JP, Rosenthal AL: Ocular pressure response to fluorometholone acetate and dexamethasone sodium phosphate. Curr Eye Res 1984;3:835-839
14. Armaly MF: Statistical attributes of the steroid hypertensive response in the clinically normal eye: I. The demonstration of three levels of response. Invest Ophthalmol 1965;4:187-197.
15. Becker B: Intraocular pressure response to topical corticosteroids. Invest Ophthalmol 1965;4:198-205.
16. Matter M, Rahi AHS, Buckley RJ: Sodium cromoglycate in the treatment of contact-lens associated giant papillary conjunctivitis. Proc VII Congress of the Eur Soc Ophthalmol 1984;383-384.
17. Mindel JS, Tavitian HO, Smith H, et al: Comparative ocular pressure elevation by medrysone, fluorometholone, and dexamethasone phosphate. Arch Ophthalmol 1980;98:1577-1578.
18. Yablonski ME, Burde RM, Kolker AE, et al: Cataracts induced by topical dexamethasone in diabetics Arch Ophthalmol 1978;96:474-476.